Cell Division Protein FtsZ - Pipeline Review, H1 2020

February 2020 | 34 pages | ID: C6D6BD7A6119EN
Global Markets Direct

Abstracts

Cell Division Protein FtsZ - Pipeline Review, H1 2020

SUMMARY

According to the recently published report 'Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2020'; Cell Division Protein FtsZ (ftsz) pipeline Target constitutes close to 6 molecules. Out of which approximately 1 molecules are developed by companies and remaining by the universities/institutes.

Cell Division Protein FtsZ (ftsz) - FtsZ is a protein encoded by the ftsZ gene. It is essential cell division protein that forms a contractile ring structure at the future cell division site. The regulation of the ring assembly controls the timing and the location of cell division. It recruits other cell division proteins to the septum to produce a new cell wall between the dividing cells. It binds GTP and shows GTPase activity.

The report 'Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2020' outlays comprehensive information on the Cell Division Protein FtsZ (ftsz) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Cell Division Protein FtsZ (ftsz) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I stages are 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Tuberculosis, Bacillus Infections, Enterococcus faecium Infections, Skin And Skin Structure Infections (SSSI) Caused By Bacteria, Staphylococcus aureus Infections, Streptococcal Pneumonia and Vancomycin-Resistant Enterococcus faecium Infections.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Cell Division Protein FtsZ (ftsz)
• The report reviews Cell Division Protein FtsZ (ftsz) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Cell Division Protein FtsZ (ftsz) targeted therapeutics and enlists all their major and minor projects
• The report assesses Cell Division Protein FtsZ (ftsz) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Cell Division Protein FtsZ (ftsz) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Cell Division Protein FtsZ (ftsz)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Cell Division Protein FtsZ (ftsz) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Cell Division Protein FtsZ (ftsz) - Overview
Cell Division Protein FtsZ (ftsz) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cell Division Protein FtsZ (ftsz) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cell Division Protein FtsZ (ftsz) - Companies Involved in Therapeutics Development
TAXIS Pharmaceuticals Inc
Cell Division Protein FtsZ (ftsz) - Drug Profiles
SBP-17GA20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ftsz for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit FtsZ for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit FtsZ for Streptococcal Pneumonia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit FtsZ for Tuberculosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TXA-709 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Division Protein FtsZ (ftsz) - Dormant Products
Cell Division Protein FtsZ (ftsz) - Product Development Milestones
Featured News & Press Releases
Sep 07, 2016: FDA Grants Special Designation to TAXIS Pharmaceuticals Experimental Antibiotic:
Jun 13, 2016: Experimental Antibiotic Treats Deadly MRSA Infection
Sep 18, 2015: TAXIS Pharmaceuticals Demonstrates Synergistic Efficacy Against MRSA And Low Resistance Frequency With TXA709/Cefdinir Combination
Jun 05, 2015: TAXIS Pharmaceuticals Announces Publication of Data Demonstrating Potential Viability of TXA709 in Combating Antibiotic Resistance
Apr 27, 2015: TAXIS Pharmaceuticals Demonstrates Clinical Potential of TXA709 in Combating Antibiotic Resistance
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by TAXIS Pharmaceuticals Inc, H1 2020
Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

TAXIS Pharmaceuticals Inc